Randomization and Interventions
All participants received SOC in accordance with the current local clinical practice for COVID-19 management, which could include supplementation with O
IL-17 inhibitor (ixekizumab 80 mg SC) 1 dose every 4 weeksLow Dose IL-2 (1.5 million IU per day) for 7 days or until dischargeIndirect IL-6 inhibitor (colchicine) orally 0.5 mg every 8 hours for 3 days, followed by 4 weeks 0.5 mg 2x/dayRandomization was performed in blocks of variable sizes facilitated by a central, concealed, web-based, automated system (RedCap, version 11.0.3). Enrolled participants were allocated (1:1:1:1) to receive ixekizumab, low-dose IL-2, indirect IL-6 inhibitor, or SOC alone. 
